KRAS and colorectal carcinoma: Although there is a tremendous advance in the CRC treatment via the use of cytotoxic agents, i.e., monoclonal antibodies to targeted therapy such as on EGF receptor [78], CRC still poses a significant threat to life as KRAS gene mutation is reported as a major cause of treatment failure in cancer therapy [89].